

November 9, 2022



# VolitionRx Limited Schedules Third Quarter 2022 Earnings Conference Call and Business Update

*Conference call to take place on Tuesday November 15 at 08:30 a.m. Eastern Time*

HENDERSON, Nev., Nov. 9, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Tuesday November 15 at 08.30 a.m. Eastern Time to discuss its financial and operating results for the third quarter 2022, in addition to providing a business update.

## **Event: VolitionRx Limited Third Quarter 2022 Earnings and Business Update Conference Call**

**Date:** Tuesday November 15, 2022

**Time:** 08:30 a.m. U.S. Eastern Time

**U.S. & Canada Dial-in:** 1-877-407-9716 (toll free)

**U.K. Dial-in:** 0 800 756 3429 (toll free)

**Toll/International:** 1-201-493-6779

**Conference ID:** 13734304

Cameron Reynolds, President and Group Chief Executive Officer of Volition, will host the call along with Terig Hughes, Group Chief Financial Officer, Dr. Tom Butera, Chief Executive Officer of Volition Veterinary Diagnostics Development LLC, and Scott Powell, Executive Vice President, Investor Relations. The call will provide an update on important events which have taken place in the third quarter of 2022 and upcoming milestones.

A live audio webcast of the conference call will also be available on the investor relations page of Volition's corporate website at <http://ir.volition.com>. In addition, a telephone replay of the call will be available until November 29, 2022. The replay dial-in numbers are 1-844-512-2921 (toll-free) in the U.S. and Canada and 1-412-317-6671 (toll) internationally. Please use replay pin number 13734304.

## **About Volition**

Volition is a multi-national epigenetics company that applies its Nucleosomics™ platform through its subsidiaries to develop simple, easy to use, cost effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. Early diagnosis and monitoring have the potential not only to prolong the life of patients but also to improve their quality of

life. The tests are based on the science of Nucleosomics™, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present.

Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and additional offices in London and Singapore.

The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. The address for Volition's website is included in this document as an inactive textual reference only.

**Media Enquiries:**

Louise Batchelor/Debra Daghish, Volition, [mediarelations@volition.com](mailto:mediarelations@volition.com) +44 (0)7557 774620

🔗 View original content: <https://www.prnewswire.com/news-releases/volitionrx-limited-schedules-third-quarter-2022-earnings-conference-call-and-business-update-301672984.html>

SOURCE VolitionRx